吴泽归+唐小玲
[摘要] 目的 探讨应用不同血液透析方式与腹膜透析对尿毒症皮肤瘙痒患者进行治疗的效果。方法 整群选择2012年6月—2014年7月在该院接受治疗的93例尿毒症皮肤瘙痒患者随机平分为A组、B组、C组各31例,分别给予血液透析、血液透析联合血液透析滤过、腹膜透析3种方式进行治疗,并对治疗效果进行比较分析。 结果 接受相应治疗后,C组治疗后瘙痒程度显著低于A组和B组,B组治疗后瘙痒程度显著低于A组(P<0.05),A组变化程度不大(P>0.05);C组患者β2-MC、iPTH、P3-均显著低于A、B两组,患者皮肤瘙痒症状的改善程度也显著优于A、B两组(P<0.05)。 结论 腹膜透析为尿毒症皮肤瘙痒的有效方式之一,其安全性高,效果好,值得临床推广应用。
[关键词] 尿毒症;皮肤瘙痒;血液透析;腹膜透析
[中图分类号] R692.5 [文献标识码] A [文章编号] 1674-0742(2015)09(a)-0063-03
Efficacy of Different Hemodialysis Modilities and Peritoneal Dialysis for Uremic Pruritus
WU Ze-gui, TANG Xiao-ling
Fourth Department of Internal Medicine, Shantou Central Hospital, Shantou, Guangdong Province, 515000 China
[Abstract] Objective To explore the efficacy of different hemodialysis modilities and peritoneal dialysis for patients with uremic pruritus. Methods 93 patients with uremic pruritus admitted to our hospital between June 2012 and July 2014 and were randomly divided into group A, group B, group C with 31 in each one. We comparatively analyzed the efficacies of three different modilities: hemodialysis, hemodialysis combined with hemodiafiltration, and peritoneal dialysis, respectively used in three groups. Results After corresponding treatment, the extent of uremic pruritus was lower in group C than group A and group B, and was lower in group B than group A, P<0.05, and that of group A showed no significant changes; The β2-MC, iPTH, and P3- were significant lower in group C than group A and group B, and the improvement on uremic pruritus in group C was superior to that in group A and group B, P<0.05. Conclusion Peritoneal dialysis is worthy of promotion in the treatment of patients with uremic pruritus because of its higher safety and better effect.
[Key words] Uremia; Pruritus; Hemodialysis; Peritoneal dialysis
临床研究结果显示,在尿毒症患者中有超过70%的患者会出现皮肤瘙痒症状,这种症状的存在对患者的生活质量造成严重影响[1]。在该次研究中,该院分别应用血液透析、血液透析联合血液透析滤过、腹膜透析3种方式对A组、B组、C组3组尿毒症皮肤瘙痒患者进行治疗,并对治疗效果进行比较,旨在分析治疗尿毒症皮肤瘙痒的最有效方法,为临床治疗提高可靠参考依据,现报道如下。
1 资料与方法
1.1 一般资料
整群选取2012年6月—2014年7月期间该院收治的93例尿毒症皮肤瘙痒患者作为研究对象,按照随机数据法将患者平分为A组、B组、C组各31例。A组患者年龄:男19例,女12例;年龄:40~72岁,平均(57.5±2.1)岁;病程:6个月~2年,平均(11.2±2.4)个月。B组患者年龄:男18例,女13例;年龄:39~76岁,平均(58.1±2.9)岁;病程:3个月~2年,平均(11.8±1.9)个月。C组患者年龄:男20例,女11例;年龄:41~78岁,平均(58.2±1.6)岁;病程:4个月~3年,平均(13.7±1.7)个月。……